Insilico Medicine has entered a multi-year research and development collaboration with Servier, an independent international pharmaceutical company governed by a foundation, to discover and develop oncology therapies. The partnership is valued at up to $888 million and pairs Insilico’s AI-driven drug discovery platforms with Servier’s global cancer drug development expertise.
Under the agreement, Insilico is eligible to receive up to $32 million in upfront and near-term R&D payments. Insilico will use its proprietary AI and automation technologies to identify and advance drug candidates that meet predefined scientific and development criteria. Servier will share R&D costs and, if promising candidates are identified, will lead clinical validation, regulatory interactions and worldwide commercialization.
Insilico highlighted its oncology pipeline, including ISM6331, a potential best-in-class pan-TEAD inhibitor, and ISM3412, a MAT2A inhibitor, both currently in global, multicenter Phase I trials. Four additional oncology programs have been fully or partially out-licensed to partners and are progressing through Phase I studies.
The company says its AI-driven approach has accelerated preclinical development timelines. Between 2021 and 2024 Insilico nominated 20 preclinical candidates, with each program reaching preclinical candidate nomination within 12 to 18 months and requiring synthesis and testing of only 60 to 200 molecules, compared with an average early-stage discovery timeline of about 4.5 years.
Leave a Reply